Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
OtherPractice

Breaking down barriers to initiating insulin

Insulin prescription pad

Alia Ali, Alice Y.Y. Cheng and Catherine H. Yu
Canadian Family Physician May 2015; 61 (5) 445-447;
Alia Ali
Resident physician in the Department of Family and Community Medicine at the University of Toronto in Ontario.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Y.Y. Cheng
Assistant Professor in the Department of Medicine at the University of Toronto.
MD FRCPC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine H. Yu
Assistant Professor in the Department of Medicine at the University of Toronto, and Associate Scientist at the Li Ka Shing Knowledge Institute of St Michael’s Hospital in Toronto.
MD MHSc FRCPC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Many patients with type 2 diabetes mellitus (T2DM) require insulin therapy to achieve and maintain glycemic control.1 Family physicians provide most of the care for these patients and are usually the first point of contact in the insulin conversation. Therefore, it is important that family physicians have the knowledge and skills to initiate and titrate insulin, and any additional tools they can use to assist them in the process would be beneficial. In this article, we describe a practical and educational tool to aid primary care physicians and diabetes specialists in insulin initiation and titration in patients with T2DM.

Barriers to insulin initiation

Optimizing glycemic control by starting insulin therapy can be delayed owing to a number of real and perceived barriers on the part of the patient, the health care provider, and the health care system.2 Patients often perceive insulin initiation as a failure3 in their management of diabetes, leading to self-blame and feelings of guilt and anxiety. Patients are also often deterred by the perceived inconvenience and lack of portability of insulin.4 Other patient and physician barriers include the fear of hypoglycemia, fear of weight gain, lack of understanding of the need for insulin, discomfort with insulin dosing and titration, and lack of time and resources, to name a few.

Identifying potential barriers and addressing concerns through counseling (including education about modern insulin-delivery devices) might improve patient acceptance.4,5 An interprofessional approach can facilitate this transition to insulin therapy through education and empowerment of the patient to engage in self-management. Fear of hypoglycemia can be addressed by recognizing and modifying risk factors for hypoglycemia, such as type and timing of insulin, missed meals, alcohol intake, and physical activity. Weight gain can be minimized through an interprofessional approach, promoting regular exercise, modifying diet, and selecting an appropriate insulin regimen. Lack of understanding of the need for insulin can be addressed through proper education about the benefits of improved glycemic control, including reduced microvascular and macrovascular complications.6 As for the barrier of discomfort with insulin dosing and titration, the insulin prescription pad (Figures 1 and 2)7 can serve as an educational and functional tool.

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Insulin-specific prescription pad: Front page.

Canadian Diabetes Association.7 Reproduced with permission from the Ontario College of Family Physicians Insulin Prescription Tool and the New Brunswick Diabetes Task Group.

Figure 2.
  • Download figure
  • Open in new tab
Figure 2.

Insulin-specific prescription pad: Back page.

Canadian Diabetes Association.7 Reproduced with permission from the Ontario College of Family Physicians Insulin Prescription Tool and the New Brunswick Diabetes Task Group.

Insulin prescription pad

The insulin-specific prescription pad (Figures 1 and 2),7 developed by the Canadian Diabetes Association and adapted from the Insulin Prescription Tool of the Ontario College of Family Physicians and the New Brunswick Diabetes Task Group, can be found at the Canadian Diabetes Association website (guidelines.diabetes.ca) and can be used free of charge. This tool is both educational and practical, facilitating the process of insulin initiation and titration.

Front page

The front page of the tool is the prescription component (Figure 1).7 To begin, a practitioner chooses the type of insulin—each section represents a type of insulin (basal, bolus, premixed). Then the practitioner selects a specific brand of insulin—manufacturer names are presented in alphabetical order and divided into columns. After selecting the specific insulin and delivery method (vial, cartridge, or prefilled pen device), the practitioner then completes the starting dose and titration schedule according to the template provided. With this tool, the physician can prescribe not only the type of insulin but also the pen device and other supplies, such as pen needles, test strips, and lancets, that are required when initiating therapy. This page can be maintained on file to monitor changes in insulin requirements and can serve as a quick guide to monitoring trends in insulin requirements.

Back page

The back of the insulin prescription pad (Figure 2)7 provides information on the 3 commonly used insulin regimens in patients with T2DM: basal, basal-bolus, and premixed insulin. With each regimen, recommendations are made with respect to target levels, starting doses, appropriate titration doses, and timing. Dosing and titration are further explained with example cases in the right-hand column.

It is often preferable to start with basal insulin because it is simple to use, causes less weight gain, and is associated with a reduced risk of hypoglycemia compared with premixed or basal-bolus regimens. Insulin combined with oral antihyperglycemic agents compared with insulin alone has similar effects on glycemic control and better effects on weight gain, lower insulin requirements, and hypoglycemia.2 The tool provides guidance on which non-insulin antihyperglycemic agents should be stopped for each regimen. Continuing metformin therapy, unless contraindicated, is encouraged to allow for improved glycemic control and less risk of weight gain and hypoglycemia. Further glucose lowering can also be achieved with combination therapy with dipeptidyl peptidase 4 inhibitors and glucagonlike peptide 1 receptor agonists. Sulfonylurea therapy can be continued with basal insulin use, but stopped when bolus insulin is added.8

The final row of the back page provides recommendations for the selection of a pen needle.

In practice

Using the insulin prescription pad in our practice has removed the uncertainty around selecting a starting insulin regimen and has provided a rational approach to titrating insulin therapy. Owing to its function as a prescription that can be completed with a few check marks and numbers, it has also increased efficiency and clarity when prescribing insulin types and the required supplies.

The insulin prescription tool is an evidence-based,9 effective, and time-saving means of starting insulin therapy in patients with T2DM. With its rational approach to titrating insulin therapy, the tool can be adapted to any patient, and patients themselves can titrate their own therapy with support from their health care providers. This tool is also great for teaching trainees. We hope that this insulin prescription tool will ease the initiation of insulin therapy and will facilitate the process of choosing an appropriate insulin regimen.

Footnotes

  • Competing interests

    Dr Cheng has received honoraria for speaking at or attending advisory board meetings of the following: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Sanofi, Janssen, Merck, Novo Nordisk, Servier, and Takeda.

  • We encourage readers to share some of their practice experience: the neat little tricks that solve difficult clinical situations. Praxis articles can be submitted online at http://mc.manuscriptcentral.com/cfp or through the CFP website (www.cfp.ca) under “Authors and Reviewers.”

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Gerstein HC,
    2. Yale JF,
    3. Harris SB,
    4. Issa M,
    5. Stewart JA,
    6. Dempsey E
    . A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med 2006;23(7):736-42.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Lau AN,
    2. Tang T,
    3. Halapy H,
    4. Thorpe K,
    5. Yu CH
    . Initiating insulin in patients with type 2 diabetes. CMAJ 2012;184(7):767-76. Epub 2012 Apr 2.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Peyrot M,
    2. Rubi RR,
    3. Lauritzen T,
    4. Skovlund SE,
    5. Snoek FJ,
    6. Matthews DR,
    7. et al
    . Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28(11):2673-9.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Brunton S
    . Insulin delivery systems: reducing barriers to insulin therapy and advancing diabetes mellitus treatment. Am J Med 2008;121(6 Suppl):S35-41.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Nakar S,
    2. Yitzhaki G,
    3. Rosenberg R,
    4. Vinker S
    . Transition to insulin in type 2 diabetes: family physicians’ misconception of patients’ fears contributes to existing barriers. J Diabetes Complications 2007;21(4):220-6.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. United Kingdom Prospective Diabetes Study Group
    . United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128(3):165-75.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Canadian Diabetes Association [website]
    . Insulin prescription tool for healthcare providers. Toronto, ON: Canadian Diabetes Association; 2013. Available from: http://guidelines.diabetes.ca/BloodGlucoseLowering/InsulinPrescriptionTool. Accessed 2015 Mar 31.
  8. 8.↵
    1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee
    . Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2013;37(Suppl 1):S1-216. Epub 2013 Mar 26.
    OpenUrlPubMed
  9. 9.↵
    1. Harper W,
    2. Clement M,
    3. Goldenberg R,
    4. Hanna A,
    5. Main A,
    6. Retnakaran R,
    7. et al
    . Pharmacologic management of type 2 diabetes. Can J Diabetes 2013;37(Suppl 1):S61-8. Epub 2013 Mar 26.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 61 (5)
Canadian Family Physician
Vol. 61, Issue 5
1 May 2015
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Breaking down barriers to initiating insulin
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Breaking down barriers to initiating insulin
Alia Ali, Alice Y.Y. Cheng, Catherine H. Yu
Canadian Family Physician May 2015, 61 (5) 445-447;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Breaking down barriers to initiating insulin
Alia Ali, Alice Y.Y. Cheng, Catherine H. Yu
Canadian Family Physician May 2015, 61 (5) 445-447;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Barriers to insulin initiation
    • Insulin prescription pad
    • In practice
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Hypoglycemia in type 2 diabetes: It is common, so what strategies can minimize the risk?
  • GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Praxis

  • Éponge à haut rebond comme outil de simulation d’une suture périnéale
  • High-rebound sponge as a simulation tool for perineal suture
  • Assessment and management of disability due to mental disorders
Show more Praxis

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire